Skip to main content

Advanced Melanoma Ignyte-3

Status: Open to Enrollment
Email us to enroll

Study details

View study details on www.clinicaltrials.gov.

Locations

  • San Francisco

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3).

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.

Kevin B Kim, M.D.
Kevin B Kim, M.D.
Principal investigator
View profile
Dron Gauchan, M.D.
Dron Gauchan, M.D.
Principal investigator
View profile

Sub-Investigators

Nitin Rohatgi, M.D., MBA, Benjamin G Coombs, D.O., Christopher J Laing, M.D., Henal H Patel, M.D., Aria Sasaki, M.D.

Email us to enroll

Related clinical trials

View all clinical trials
  • Clinical trial

    Advanced Melanoma Mirdametinib CPMC24-MEL01

    A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01)

    Status: Open to Enrollment

  • Clinical trial

    Advanced Staged Cancer Targeted Therapy ASCO TAPUR

    Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • Clinical trial

    Adverse Effects of Chemotherapy Shengbai Solution

    A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB

    FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advanced Pancreatic Adenocarcinoma

    Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?